PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Evolocumab prevents carotid artery wall thickening in paediatric HeFH PCSK9 plays critical role in abdominal aortic aneurysm Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD

Latest News Updates

9th Closed Scientific Expert Meeting of the Editorial Board

24th August 2018, Munich, Germany (Educational supporters)

ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)

ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)

Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Gregory Schwartz and Michael Szarek

Posted on 11 December 2018 | Posted by Gregory G. Schwartz, Michael Szarek | Posted in Webcasts, 9th Closed Scientific Expert Meeting of the Editorial Board

Lp(a) and CV risk: Insights from the FOURIER trial

Lp(a) and CV risk: Insights from the FOURIER trial

Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Dr Erin Bohula

Posted on 3 December 2018 | Posted by Erin Bohula | Posted in Webcasts, 9th Closed Scientific Expert Meeting of the Editorial Board

Genetics of Lp(a) and CVD

Genetics of Lp(a) and CVD

Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor Anne Tybjærg-Hansen

Posted on 3 December 2018 | Posted by Anne Tybjaerg-Hansen | Posted in Webcasts, 9th Closed Scientific Expert Meeting of the Editorial Board

$Do LDL subfractions matter?$

Do LDL subfractions matter?

Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor John Chapman

Posted on 9 November 2018 | Posted by John Chapman | Posted in Webcasts, 9th Closed Scientific Expert Meeting of the Editorial Board

PCSK9 and the adrenals: how are cholesterol levels protected?

PCSK9 and the adrenals: how are cholesterol levels protected?

Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor Bo Angelin

Posted on 9 November 2018 | Posted by Bo Angelin | Posted in Webcasts, 9th Closed Scientific Expert Meeting of the Editorial Board

Does one plaque characteristic fit all?

Does one plaque characteristic fit all?

Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor Gerard Pasterkamp

Posted on 9 November 2018 | Posted by Gerard Pasterkamp | Posted in Webcasts, 9th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved